Long-term clinical, radiological, and safety outcomes during fingolimod treatment in relapsing–remitting multiple sclerosis: a real-world cohort from Saudi Arabia
Fingolimod, a sphingosine-1-phosphate receptor modulator, has demonstrated robust efficacy in relapsing–remitting multiple sclerosis (RRMS). However, real-world long-term data from Middle Eastern populations remain limited. This study aimed to describe long-term clinical, radiological, laboratory, and cardiac outcomes...